Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	52.82 $	+0.57%	44,80,359
06/26/06	52.52 $	-2.43%	1,24,32,558
05/26/05	53.83 $	-6.87%	1,39,53,534
04/26/04	57.80 $	+15.99%	2,31,03,642
03/26/03	49.83 $	-5.71%	92,58,801

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Moderna in a Spin After FDA Declines to Review Flu Vaccine Candidate

February 11, 2026 at 08:43 pm IST

Moderna Falls As FDA Vows To Impose New Vaccine Rules

December 02, 2025 at 02:02 am IST

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

52.52USD

Average target price

42.90USD

Spread / Average Target

-18.32%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 08:40:56 09/03/2026 pm IST			5-day change	1st Jan Change
52.52 ^USD	0.00%		-0.39%	+78.50%

05/03	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
05/03	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE

Capitalization	2.07TCr 1.79TCr 1.61TCr 1.55TCr 2.82TCr 1,90600Cr 2.96TCr 19TCr 7.65TCr 91TCr 7.78TCr 7.62TCr 3,26900Cr	P/E ratio 2026 *	-7.57x	P/E ratio 2027 *	-11.5x
Enterprise value	1.69TCr 1.46TCr 1.31TCr 1.26TCr 2.3TCr 1,55100Cr 2.41TCr 16TCr 6.22TCr 74TCr 6.33TCr 6.2TCr 2,66000Cr	EV / Sales 2026 *	8.17x	EV / Sales 2027 *	7.23x
Free-Float	90.48%	Yield 2026 *	-	Yield 2027 *	-

05/03	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
05/03	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
05/03	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
05/03	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT
05/03	US Equity Markets End Higher After Strong Services, Jobs Data	MT
05/03	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
05/03	Equities Rise Intraday as Markets Parse Macro Data Amid Middle East Conflict	MT
04/03	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
04/03	Wall Street mixed as oil retreat eases inflation fears
04/03	Top Midday Stories: Bessent Says US to Fortify Gulf Oil Trade, 15% Tariff Rolling Out This Week; CrowdStrike Fiscal Q4 Adjusted Earnings, Revenue Increase	MT
04/03	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
04/03	Global markets live: Goldman Sachs, Meta, Intel, Moderna, Adidas…
04/03	Moderna to pay $950m to end litigation

05/03	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
27/02	Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating	MT
26/02	Analyst recommendations: Spotify, Gartner, Godaddy, Medline, Moderna…
17/02	Bernstein Adjusts Price Target on Moderna to $45 From $35, Maintains Market Perform Rating	MT
17/02	RBC Capital Adjusts Price Target on Moderna to $30 From $25, Maintains Sector Perform Rating	MT

Moderna, Inc. Share Price

Equities

MRNA

US60770K1079

Pharmaceuticals

Valuation: Moderna, Inc.

Chart: Moderna, Inc.

Latest news: Moderna, Inc.

Last Transcript: Moderna, Inc.

Analysts' recommendations: Moderna, Inc.

Press Releases: Moderna, Inc.

News in other languages: Moderna, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Moderna, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

28/02	Moderna : Transcript (MRNA USQ Transcript 2026 01 13 3)	PU
18/02	Moderna says the FDA will consider its new flu shot after resolving a public dispute	AQ
14/02	Moderna : Earnings Transcript (MRNA USQ Transcript 2026 02 13)	PU
13/02	Moderna : Earnings Presentation (ModernaQ25inal)	PU
13/02	Moderna: Q4 Earnings Snapshot	AQ

05/03	Wall Street progresse après des signes d'ouverture de l'Iran à des discussions avec Washington
05/03	Aktien New York Schluss: Erholung - Gute Daten und Entspannung beim Öl
05/03	MÄRKTE USA/Börsen lassen Iran-Konflikt hinter sich - Chipwerte gefragt
05/03	Wall Street surmonte les incertitudes liées à la guerre au Moyen-Orient
04/03	MÄRKTE USA/Erholung nimmt im Handelsverlauf Fahrt auf

1 day	+0.02%
1 week	-0.39%
Current month	-1.74%
1 month	+25.48%
3 months	+86.40%
6 months	+115.12%
Current year	+78.50%

1 week	48.09	59.55
1 month	36.66	59.55
Current year	29.81	59.55
1 year	22.28	59.55
3 years	22.28	170.47
5 years	22.28	497.49
10 years	11.54	497.49

Manager	Title	Age	Since
Stéphane Bancel CEO	Chief Executive Officer	54	01/03/2011
James Mock DFI	Director of Finance/CFO	49	06/09/2022
Stephen Hoge PSD	President	50	01/11/2024

Director	Title	Age	Since
Paul Sagan BRD	Director/Board Member	66	01/06/2018
Noubar Afeyan CHM	Chairman	62	01/02/2012
Stéphane Bancel BRD	Director/Board Member	54	01/03/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MODERNA, INC.	0.00%	-0.39%	+46.38%	-61.68%	2.07TCr
REGENERON PHARMACEUTICALS, INC.	+1.17%	-3.80%	+2.14%	+2.28%	7.8TCr
UCB	+1.00%	+1.52%	+49.59%	+213.54%	5.54TCr
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	+57.90%	+57.90%	+57.90%	5.12TCr
CSL LIMITED	-2.77%	-3.09%	-45.23%	-52.13%	4.94TCr
BIOGEN INC.	-0.09%	-2.36%	+21.83%	-29.10%	2.71TCr
INCYTE CORPORATION	-0.52%	-5.05%	+33.54%	+30.37%	1.91TCr
INNOVENT BIOLOGICS, INC.	-1.86%	-3.94%	+103.36%	+104.89%	1.85TCr
SWEDISH ORPHAN BIOVITRUM AB	-0.58%	-4.12%	+25.39%	+53.95%	1.41TCr
ALTEOGEN INC.	-1.74%	-10.06%	-0.54%	+915.24%	1.34TCr
Average	-0.95%	-3.38%	+29.44%	+123.53%	3.47TCr
Weighted average by Cap.	-0.79%	-3.20%	+23.36%	+74.66%

	2026 *	2027 *
Net sales	206.69Cr 178.21Cr 160.87Cr 154.36Cr 281.47Cr 19TCr 294.57Cr 1.9TCr 761.88Cr 9.11TCr 775.73Cr 759.19Cr 33TCr	253.17Cr 218.28Cr 197.05Cr 189.07Cr 344.77Cr 23TCr 360.82Cr 2.33TCr 933.2Cr 11TCr 950.16Cr 929.91Cr 40TCr
Net income	-273.83Cr -236.1Cr -213.13Cr -204.5Cr -372.91Cr -25TCr -390.26Cr -2.52TCr -1.01TCr -12TCr -1.03TCr -1.01TCr -43TCr	-181.72Cr -156.68Cr -141.44Cr -135.71Cr -247.47Cr -17TCr -258.99Cr -1.67TCr -669.84Cr -8.01TCr -682.02Cr -667.48Cr -29TCr
Net Debt	-386.48Cr -333.22Cr -300.81Cr -288.63Cr -526.31Cr -36TCr -550.81Cr -3.56TCr -1.42TCr -17TCr -1.45TCr -1.42TCr -61TCr	-244.42Cr -210.74Cr -190.24Cr -182.54Cr -332.86Cr -22TCr -348.35Cr -2.25TCr -900.96Cr -11TCr -917.34Cr -897.78Cr -39TCr